Long-COVID Symptoms Improved after MDMA and Psilocybin Therapy: a case report
Harman Chopra, Timothy Furnish, Monica Verduzco-Gutierrez, David S Jevotovsky, Joel Castellanos
April 2, 2024 DOI: 10.22541/au.171206643.31518756/v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report |
|---|---|
| Topics | MDMA Psilocybin |
Abstract
IntroductionCoronavirus disease 2019 (COVID-19) is a highly contagious respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was first identified in Wuhan, China in December 2019 and has since spread
Citations in the library
Cites 3
- Default Mode Network Modulation by Psychedelics: A Systematic Review The International Journal of Neuropsychopharmacology October 21, 2022
- The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. Cureus September 1, 2022
- Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems Frontiers in Psychiatry September 6, 2021